Skip to main content
. Author manuscript; available in PMC: 2013 Mar 8.
Published in final edited form as: Transfusion. 2011 Apr 22;51(10):2168–2174. doi: 10.1111/j.1537-2995.2011.03145.x

Fig. 3.

Fig. 3

Reactions of 20 serum samples containing HNA-3a–specific antibodies implicated in TRALI with oxidized (cyclic) and linear 36-mer CTL2 peptides D131-K166 containing R or Q at Position 154. (A) Antibodies 1, 5, 8, 9, 10, 11, 17, 18, and 20 reacted preferentially with the R154 form of the cyclic peptide. (B) Antibodies 5, 8, 9, 10, 11, 17, 18, and 19 reacted preferentially with the R154 form of the linear peptide. Results shown are mean ± 1 SD OD of triplicate measurements in ELISA. Asterisks indicate p < 0.001 (cyclic peptide) and p < 0.002 (linear peptide) for sera with preferential reaction against D131-K166 (R154). Dotted line is mean + 1 SD OD obtained with sera from 10 normal donors against the R154 peptide; dashed line indicates mean + 1 SD optical density obtained with normal sera against the Q154 peptide.